Rossella Medori - Publications

Affiliations: 
Università di Bologna, Bologna, Italy 

69 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 25921050 DOI: 10.1177/1352458515581436  0.92
2015 Magistrale G, Pisani V, Argento O, Incerti CC, Bozzali M, Cadavid D, Caltagirone C, Medori R, DeLuca J, Nocentini U. Validation of the World Health Organization Disability Assessment Schedule II (WHODAS-II) in patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 448-56. PMID 25092769 DOI: 10.1177/1352458514543732  0.92
2014 Phillips GA, Wyrwich KW, Guo S, Medori R, Altincatal A, Wagner L, Elkins J. Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1753-60. PMID 24740371 DOI: 10.1177/1352458514530489  0.92
2012 Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, Whalley ET, Davis JA, Versage EM, Richert JR, Axtell RC, Steinman L, Medori R. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology. 79: 531-7. PMID 22573631 DOI: 10.1212/WNL.0b013e318259e123  0.92
2010 Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. European Child & Adolescent Psychiatry. 19: 325-40. PMID 19823900 DOI: 10.1007/s00787-009-0056-1  0.92
2009 Mauri MC, Turner M, Volonteri LS, Medori R, Maier W. Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg. International Journal of Psychiatry in Clinical Practice. 13: 36-47. PMID 24946121 DOI: 10.1080/13651500802411979  0.92
2009 Buitelaar JK, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Konofal E, Dejonckheere J, Challis BH, Medori R. Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment. 5: 457-66. PMID 19777067  0.92
2008 Bräunig P, Sacchetti E, Medori R. Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study. International Journal of Psychiatry in Clinical Practice. 12: 74-7. PMID 24916500 DOI: 10.1080/13651500701538161  0.92
2008 Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clinical Therapeutics. 30: 2378-86. PMID 19167596 DOI: 10.1016/j.clinthera.2008.12.020  0.92
2008 Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. International Clinical Psychopharmacology. 23: 325-31. PMID 18854720 DOI: 10.1097/YIC.0b013e32830c2042  0.92
2008 Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. Journal of Clinical Psychopharmacology. 28: 210-3. PMID 18344732 DOI: 10.1097/JCP.0b013e318167269d  0.92
2008 Curtis VA, Katsafouros K, Möller HJ, Medori R, Sacchetti E. Long-acting risperidone improves negative symptoms in stable psychotic patients. Journal of Psychopharmacology (Oxford, England). 22: 254-61. PMID 18308804 DOI: 10.1177/0269881107082119  0.92
2008 Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. International Journal of Clinical Pharmacology and Therapeutics. 46: 14-22. PMID 18218293  0.92
2008 Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry. 63: 981-9. PMID 18206857 DOI: 10.1016/j.biopsych.2007.11.008  0.92
2008 Rabinowitz J, Levine SZ, Medori R, Oosthuizen P, Koen L, Emsley R. Concordance of patient and clinical ratings of symptom severity and change of psychotic illness. Schizophrenia Research. 100: 359-60. PMID 18077138 DOI: 10.1016/j.schres.2007.10.021  0.92
2008 Emsley R, Medori R, Koen L. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study (Journal of Clinical Psychopharmacology (2008) 28 (210-213)) Journal of Clinical Psychopharmacology. 28: 624. DOI: 10.1097/01.JCP.0000341486.30638.67  0.92
2007 Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry. 40: 257-63. PMID 18030649 DOI: 10.1055/s-2007-992140  0.92
2007 Kissling W, Glue P, Medori R, Simpson S. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Human Psychopharmacology. 22: 505-13. PMID 17902187 DOI: 10.1002/hup.877  0.92
2007 Schmauss M, Sacchetti E, Kahn JP, Medori R. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. International Clinical Psychopharmacology. 22: 85-92. PMID 17293708 DOI: 10.1097/YIC.0b013e3280119ddb  0.92
2007 Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. Schizophrenia Research. 89: 129-39. PMID 17095194 DOI: 10.1016/j.schres.2006.09.013  0.92
2006 Heger S, Trott GE, Meusers M, Schulz E, Rothenberger A, Rettig K, Medori R, Schreiner A, Remschmidt H. [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD]. Zeitschrift FüR Kinder- Und Jugendpsychiatrie Und Psychotherapie. 34: 257-65. PMID 16927568 DOI: 10.1024/1422-4917.34.4.257  0.92
2006 Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. The American Journal of Psychiatry. 163: 743-5. PMID 16585455 DOI: 10.1176/appi.ajp.163.4.743  0.92
2006 Currier GW, Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. Journal of Psychiatric Practice. 12: 30-40. PMID 16432443 DOI: 10.1097/00131746-200601000-00005  0.92
2006 Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 16: 233-40. PMID 16326078 DOI: 10.1016/j.euroneuro.2005.10.006  0.92
2005 Hoare P, Remschmidt H, Medori R, Ettrich C, Rothenberger A, Santosh P, Schmit M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. European Child & Adolescent Psychiatry. 14: 305-9. PMID 16220214 DOI: 10.1007/s00787-005-0486-3  0.92
2005 Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE, Medori R. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study. European Child & Adolescent Psychiatry. 14: 297-304. PMID 16220213 DOI: 10.1007/s00787-005-0467-6  0.92
2005 Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. Journal of Psychopharmacology (Oxford, England). 19: 32-8. PMID 16144784 DOI: 10.1177/0269881105056598  0.92
2005 Mohl A, Westlye K, Opjordsmoen S, Lex A, Schreiner A, Benoit M, Bräunig P, Medori R. Long-acting risperidone in stable patients with schizoaffective disorder. Journal of Psychopharmacology (Oxford, England). 19: 22-31. PMID 16144783 DOI: 10.1177/0269881105056515  0.92
2005 Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, Llorca PM. Direct transition to long-acting risperidone--analysis of long-term efficacy. Journal of Psychopharmacology (Oxford, England). 19: 15-21. PMID 16144782 DOI: 10.1177/0269881105056514  0.92
2005 Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, Medori R, Gaebel W. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. Journal of Psychopharmacology (Oxford, England). 19: 5-14. PMID 16144781 DOI: 10.1177/0269881105056513  0.92
2005 Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology. 20: 121-30. PMID 15812261 DOI: 10.1097/00004850-200505000-00001  0.92
2004 Lejeune J, Larmo I, Chrzanowski W, Witte R, Karavatos A, Schreiner A, Lex A, Medori R. Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. International Clinical Psychopharmacology. 19: 259-69. PMID 15289699 DOI: 10.1097/01.yic.0000138820.78121.0e  0.92
2003 Diehl A, Braus DF, Büchel C, Krumm B, Medori R, Gattaz WF. [Tardive dyskinesia: pergolid, a possible therapeutic option]. Psychiatrische Praxis. 30: 333-7. PMID 12970819 DOI: 10.1055/s-2003-42166  0.92
1999 Wetter TC, Stiasny K, Winkelmann J, Buhlinger A, Brandenburg U, Penzel T, Medori R, Rubin M, Oertel WH, Trenkwalder C. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology. 52: 944-50. PMID 10102410  0.92
1997 De Stefano ME, Zaccaria ML, Cavaldesi M, Petrucci TC, Medori R, Paggi P. Dystrophin and its isoforms in a sympathetic ganglion of normal and dystrophic mdx mice: immunolocalization by electron microscopy and biochemical characterization. Neuroscience. 80: 613-24. PMID 9284362 DOI: 10.1016/S0306-4522(97)00003-1  0.92
1996 Barbiroli B, Medori R, Tritschler HJ, Iotti S, Lodi R, Zaniol P. Thioctic acid stimulates muscle ATP production in patients with type 2-diabetes and diabetic polyneuropathy. An in vivo phosphorus magnetic resonance spectroscopy study Diabetes Und Stoffwechsel. 5: 71-76.  0.92
1995 Collinge J, Palmer MS, Sidle KC, Gowland I, Medori R, Ironside J, Lantos P. Transmission of fatal familial insomnia to laboratory animals. Lancet. 346: 569-70. PMID 7658786 DOI: 10.1016/S0140-6736(95)91405-6  0.92
1995 Barbiroli B, Medori R, Tritschler HJ, Klopstock T, Seibel P, Reichmann H, Iotti S, Lodi R, Zaniol P. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. Journal of Neurology. 242: 472-7. PMID 7595680 DOI: 10.1007/BF00873552  0.92
1994 Fujii T, Van Coster RN, Old SE, Medori R, Winter S, Gubits RM, Matthews PM, Brown RM, Brown GK, Dahl HH. Pyruvate dehydrogenase deficiency: molecular basis for intrafamilial heterogeneity. Annals of Neurology. 36: 83-9. PMID 8024267 DOI: 10.1002/ana.410360116  0.92
1994 Tritschler HJ, Packer L, Medori R. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Biochemistry and Molecular Biology International. 34: 169-81. PMID 7849618  0.92
1993 Tritschler HJ, Medori R. Mitochondrial DNA alterations as a source of human disorders. Neurology. 43: 280-8. PMID 8437690  0.92
1993 Minetti C, Tanji K, Chang HW, Medori R, Cordone G, DiMauro S, Bonilla E. Dystrophinopathy in two young boys with exercise-induced cramps and myoglobinuria. European Journal of Pediatrics. 152: 848-51. PMID 8223790 DOI: 10.1007/BF02073385  0.92
1993 Medori R, Tritschler HJ. Prion protein gene analysis in three kindreds with fatal familial insomnia (FFI): codon 178 mutation and codon 129 polymorphism. American Journal of Human Genetics. 53: 822-7. PMID 8105681  0.92
1992 Manetto V, Medori R, Cortelli P, Montagna P, Tinuper P, Baruzzi A, Rancurel G, Hauw JJ, Vanderhaeghen JJ, Mailleux P. Fatal familial insomnia: clinical and pathologic study of five new cases. Neurology. 42: 312-9. PMID 1736158  0.92
1992 Prelle A, Medori R, Moggio M, Chan HW, Gallanti A, Scarlato G, Bonilla E. Dystrophin deficiency in a case of congenital myopathy. Journal of Neurology. 239: 76-8. PMID 1552307 DOI: 10.1007/BF00862976  0.92
1992 Medori R, Tritschler HJ, Gambetti P. Production of single-stranded DNA for sequencing: an alternative approach. Biotechniques. 12: 346-50. PMID 1349213  0.92
1992 Medori R, Montagna P, Tritschler HJ, LeBlanc A, Cortelli P, Tinuper P, Lugaresi E, Gambetti P. Fatal familial insomnia: a second kindred with mutation of prion protein gene at codon 178. Neurology. 42: 669-70. PMID 1347910  0.92
1992 Medori R, Tritschler HJ, LeBlanc A, Villare F, Manetto V, Chen HY, Xue R, Leal S, Montagna P, Cortelli P. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. The New England Journal of Medicine. 326: 444-9. PMID 1346338 DOI: 10.1056/NEJM199202133260704  0.92
1991 Bonilla E, Minetti C, Chang HW, Medori R, Cordone G, Di Mauro S. [Clinical,manifestations of the myopathies due to deletions/mutations of the dystrophin gene]. Minerva Pediatrica. 43: 67-70. PMID 1870528  0.92
1991 McDonald TD, Medori R, Younger DS, Chang HW, Minetti C, Uncini A, Bonilla E, Hays AP, Lovelace RE. Becker muscular dystrophy or spinal muscular atrophy?--Dystrophin studies resolve conflicting results of electromyography and muscle biopsy. Neuromuscular Disorders : Nmd. 1: 195-200. PMID 1822794 DOI: 10.1016/0960-8966(91)90024-M  0.92
1991 Minetti C, Chang HW, Medori R, Prelle A, Moggio M, Johnsen SD, Bonilla E. Dystrophin deficiency in young girls with sporadic myopathy and normal karyotype. Neurology. 41: 1288-92. PMID 1714059  0.92
1990 Bonilla E, Younger DS, Chang HW, Tantravahi U, Miranda AF, Medori R, DiMauro S, Warburton D, Rowland LP. Partial dystrophin deficiency in monozygous twin carriers of the Duchenne gene discordant for clinical myopathy. Neurology. 40: 1267-70. PMID 2199849  0.92
1989 Medori R, Brooke MH, Waterston RH. Two dissimilar brothers with Becker's dystrophy have an identical genetic defect. Neurology. 39: 1493-6. PMID 2682349  0.92
1989 Medori R, Brooke MH, Waterston RH. Genetic abnormalities in Duchenne and Becker dystrophies: clinical correlations. Neurology. 39: 461-5. PMID 2648185  0.92
1989 Tinuper P, Montagna P, Medori R, Cortelli P, Zucconi M, Baruzzi A, Lugaresi E. The thalamus participates in the regulation of the sleep-waking cycle. A clinico-pathological study in fatal familial thalamic degeneration. Electroencephalography and Clinical Neurophysiology. 73: 117-23. PMID 2473878 DOI: 10.1016/0013-4694(89)90190-9  0.92
1988 Medori R, Jenich H, Autilio-Gambetti L, Gambetti P. Experimental diabetic neuropathy: similar changes of slow axonal transport and axonal size in different animal models. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 8: 1814-21. PMID 3367221  0.92
1988 Montagna P, Gallassi R, Medori R, Govoni E, Zeviani M, Di Mauro S, Lugaresi E, Andermann F. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology. 38: 751-4. PMID 3362373  0.92
1988 Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loike JD, Harris JB, Waterston R, Brooke M, Specht L. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. The New England Journal of Medicine. 318: 1363-8. PMID 3285207 DOI: 10.1056/NEJM198805263182104  0.92
1988 Medori R, Autilio-Gambetti L, Jenich H, Gambetti P. Changes in axon size and slow axonal transport are related in experimental diabetic neuropathy. Neurology. 38: 597-601. PMID 2451191  0.92
1987 Lugaresi A, Baruzzi A, Cacciari E, Cortelli P, Medori R, Montagna P, Tinuper P, Zucconi M, Roiter I, Lugaresi E. Lack of vegetative and endocrine circadian rhythms in fatal familial thalamic degeneration. Clinical Endocrinology. 26: 573-80. PMID 3665119  0.92
1987 Montagna P, Liguori R, Medori R, Daidone R, Gallassi R. Cranial bone density in motor neuron disease (MND) Italian Journal of Neurological Sciences. 8: 73-4. PMID 3570726 DOI: 10.1007/BF02361440  0.92
1986 Lugaresi E, Montagna P, Baruzzi A, Cortelli P, Tinuper P, Zucconi M, Gambetti PL, Medori R. [Familial insomnia with a malignant course: a new thalamic disease]. Revue Neurologique. 142: 791-2. PMID 3823713  0.48
1986 Lugaresi E, Medori R, Montagna P, Baruzzi A, Cortelli P, Lugaresi A, Tinuper P, Zucconi M, Gambetti P. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. The New England Journal of Medicine. 315: 997-1003. PMID 3762620 DOI: 10.1056/NEJM198610163151605  0.92
1986 Sayre LM, Shearson CM, Wongmongkolrit T, Medori R, Gambetti P. Structural basis of gamma-diketone neurotoxicity: non-neurotoxicity of 3,3-dimethyl-2,5-hexanedione, a gamma-diketone incapable of pyrrole formation. Toxicology and Applied Pharmacology. 84: 36-44. PMID 3715867 DOI: 10.1016/0041-008X(86)90414-X  0.92
1985 Montagna P, Medori R, Liguori R, Cortelli P. Abdominal neuropathy after renal surgery. Italian Journal of Neurological Sciences. 6: 357-8. PMID 4066272 DOI: 10.1007/BF02232015  0.92
1985 Montagna P, Liguori R, Medori R, Zappia M. Diurnal fluctuations of human nerve conduction velocity. Acta Neurologica Scandinavica. 71: 249-51. PMID 4039517  0.92
1985 Medori R, Autilio-Gambetti L, Monaco S, Gambetti P. Experimental diabetic neuropathy: impairment of slow transport with changes in axon cross-sectional area. Proceedings of the National Academy of Sciences of the United States of America. 82: 7716-20. PMID 2415969  0.92
1984 Coccagna C, Cirignotta F, Zucconi M, Gerardi R, Medori R, Lugaresi E. A polygraphic study of one case of primary alveolar hypoventilation (Ondine's curse). Bulletin EuropéEn De Physiopathologie Respiratoire. 20: 157-61. PMID 6722366  0.92
1984 Montagna P, Medori R, Zappia M, Gallassi R. Gowers local panatrophy. Italian Journal of Neurological Sciences. 5: 457-9. PMID 6530367 DOI: 10.1007/BF02042632  0.92
Show low-probability matches.